MarketCap
Facebook
X
Telegram
LogicBio Therapeutics Operating Income | LOGC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -39 M | -31.5 M | -41 M | -17.9 M | -5.85 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.85 M | -41 M | -27.1 M |
Quarterly Operating Income LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -5.74 M | -4.89 M | -6.45 M | - | -9.94 M | -10.2 M | -10 M | - | -7.77 M | -7.96 M | -9.34 M | - | -11 M | -10.5 M | -8.12 M | - | -4.55 M | -3.64 M | -2.37 M | - | -1.05 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.05 M | -11 M | -7.1 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
-76.4 M | $ 5.32 | 0.09 % | $ 652 M |  USA |
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.05 | 0.46 % | $ 133 M |  Schweiz |
 |
Agenus
AGEN
|
-20.2 M | $ 7.21 | 0.7 % | $ 214 M | USA |
 |
Akebia Therapeutics
AKBA
|
23.5 M | $ 0.92 | 1.64 % | $ 237 M | USA |
 |
Alector
ALEC
|
-156 M | $ 1.93 | 0.81 % | $ 199 M | USA |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
-88 M | $ 5.05 | 1.2 % | $ 49.9 M | USA |
 |
Alkermes plc
ALKS
|
254 M | $ 46.07 | 0.09 % | $ 7.59 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
-209 M | $ 1.69 | 0.58 % | $ 373 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 239.36 | 0.46 % | $ 31.4 B | USA |
 |
Altimmune
ALT
|
-94.5 M | $ 3.24 | 0.31 % | $ 285 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-104 M | $ 1.76 | 0.53 % | $ 94.4 M | USA |
 |
Evelo Biosciences
EVLO
|
-108 M | - | -14.46 % | $ 27.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 23.95 | 1.31 % | $ 1.12 B | USA |
 |
AnaptysBio
ANAB
|
47.9 M | $ 54.31 | 0.15 % | $ 1.56 B | USA |
 |
Anika Therapeutics
ANIK
|
-11.1 M | $ 20.84 | 0.24 % | $ 299 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
111 M | $ 73.59 | 2.05 % | $ 1.48 B | USA |
 |
Aptevo Therapeutics
APVO
|
-26.3 M | $ 1.72 | 0.58 % | $ 543 K | USA |
 |
Allakos
ALLK
|
-122 M | - | - | $ 28.6 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.82 | 0.21 % | $ 515 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 15.6 | 0.25 % | $ 427 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
-36.6 M | $ 4.07 | 2.21 % | $ 147 M | USA |
 |
Assembly Biosciences
ASMB
|
-12.1 M | $ 25.48 | 0.54 % | $ 286 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-36.2 M | $ 1.24 | 0.79 % | $ 38.7 M | USA |
 |
AbbVie
ABBV
|
15.1 B | $ 262.51 | 0.01 % | $ 464 B | USA |
 |
Atara Biotherapeutics
ATRA
|
35.9 M | $ 10.11 | 7.1 % | $ 127 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
33.2 M | $ 16.96 | 5.15 % | $ 2.28 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.87 | 0.53 % | $ 498 M | Britain |
 |
Atea Pharmaceuticals
AVIR
|
-181 M | $ 5.15 | 1.24 % | $ 420 M | USA |
 |
Axon Enterprise
AXON
|
-62.1 M | $ 468.42 | 5.96 % | $ 36.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 211.97 | 3.87 % | $ 10.5 B | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 1.97 | 0.5 % | $ 12.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
-523 M | $ 68.3 | 0.1 % | $ 13.1 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-247 M | $ 3.64 | 0.68 % | $ 252 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
12.5 M | $ 1.94 | 1.02 % | $ 110 M | USA |
 |
Beam Therapeutics
BEAM
|
-384 M | $ 23.1 | 0.15 % | $ 2.28 B | USA |
 |
Biogen
BIIB
|
7.04 B | $ 216.01 | 0.42 % | $ 31.6 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 2.48 | 0.79 % | $ 6.11 B | Israel |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 11.67 | 2.28 % | $ 3.49 B | Canada |
 |
Benitec Biopharma
BNTC
|
-51.2 M | $ 11.04 | 0.9 % | $ 514 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Burford Capital Limited
BUR
|
232 M | $ 3.87 | 0.8 % | $ 848 M | Britain |
 |
Clovis Oncology
CLVS
|
-52.7 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-96.6 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
Cabaletta Bio
CABA
|
-172 M | $ 2.49 | 0.39 % | $ 250 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.24 | 0.89 % | $ 3.69 M | Israel |
 |
Catalyst Biosciences
CBIO
|
11.5 M | $ 17.18 | 1.7 % | $ 1.53 B | USA |
 |
C4 Therapeutics
CCCC
|
-115 M | $ 3.45 | 0.58 % | $ 286 M | USA |